Literature DB >> 1558082

Comorbidity of fibromyalgia with medical and psychiatric disorders.

J I Hudson1, D L Goldenberg, H G Pope, P E Keck, L Schlesinger.   

Abstract

PURPOSE: Patients with fibromyalgia have been reported to display high rates of several concomitant medical and psychiatric disorders, including migraine, irritable bowel syndrome, chronic fatigue syndrome, major depression, and panic disorder. To test further these and other possible associations, we assessed the personal and family histories of a broad range of medical and psychiatric disorders in patients with fibromyalgia. PATIENTS AND METHODS: Subjects were 33 women (mean age 42.1 years) who each met American College of Rheumatology criteria for fibromyalgia and presented to a rheumatologist at a tertiary referral center. They received the Structured Clinical Interview for DSM-III-R (SCID); a supplemental interview, in SCID format, for other medical and psychiatric disorders, including migraine, irritable bowel syndrome, and chronic fatigue syndrome; and an interview for family history of medical and psychiatric disorders.
RESULTS: Patients with fibromyalgia displayed high lifetime rates of migraine, irritable bowel syndrome, chronic fatigue syndrome, major depression, and panic disorder. They also exhibited high rates of familial major mood disorder.
CONCLUSIONS: The finding that migraine, irritable bowel syndrome, chronic fatigue syndrome, major depression, and panic disorder are frequently comorbid with fibromyalgia is consistent with the hypothesis that these various disorders may share a common physiologic abnormality.

Entities:  

Mesh:

Year:  1992        PMID: 1558082     DOI: 10.1016/0002-9343(92)90265-d

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  74 in total

1.  Treatment of fibromyalgia with antidepressants: a meta-analysis.

Authors:  P G O'Malley; E Balden; G Tomkins; J Santoro; K Kroenke; J L Jackson
Journal:  J Gen Intern Med       Date:  2000-09       Impact factor: 5.128

2.  Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression.

Authors:  K Fassbender; W Samborsky; M Kellner; W Müller; S Lautenbacher
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

3.  Mechanical and heat hyperalgesia highly predict clinical pain intensity in patients with chronic musculoskeletal pain syndromes.

Authors:  Roland Staud; Elizabeth E Weyl; Donald D Price; Michael E Robinson
Journal:  J Pain       Date:  2012-06-26       Impact factor: 5.820

4.  Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia.

Authors:  Leonard A Jason; Stephanie McManimen; Madison Sunnquist; Julia L Newton; Elin Bolle Strand
Journal:  Neurology (ECronicon)       Date:  2017-03-08

Review 5.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol
Journal:  Rheumatol Int       Date:  2005-11-20       Impact factor: 2.631

Review 6.  Psychiatric comorbidity in fibromyalgia.

Authors:  Laurence A Bradley
Journal:  Curr Pain Headache Rep       Date:  2005-04

7.  Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert L Burr; Kevin C Cain; Vicky Hertig; Pam Weisman; Margaret M Heitkemper
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 8.  A realistic approach to managing patients with fibromyalgia.

Authors:  Geoffrey O Littlejohn; Janine Walker
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

9.  Clinical screening for narcolepsy/cataplexy in patients with fibromyalgia.

Authors:  P Disdier; P Genton; G Bolla; D Verrot; C Christides; J R Harlé; P J Weiller
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 10.  Predictors of clinical pain intensity in patients with fibromyalgia syndrome.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.